Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case

Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case

Despite the high initial susceptibility of ovarian cancer (OC) to chemotherapy, the vast majority of patients with Stages III–IV of the disease have its recurrences. Chemotherapy is a main treatment for recurrent OC. In Russia, the rate of platinum-resistant recurrences after first-line chemotherapy...

Full description

Bibliographic Details
Main Authors:	I. A. Pokataev, A. S. Tyulyandina, L. V. Chitia, S. A. Tyulyandin
Format:	Article
Language:	Russian
Published:	ABV-press 2015-11-01
Series:	Opuholi Ženskoj Reproduktivnoj Sistemy
Subjects:	ovarian cancer chemotherapy platinum-resistant recurrence pegylated liposomal doxorubicin trabectedin platinum-free interval drug resistance predictors of chemotherapy effectiveness
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/463

Similar Items

Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
by: Zhen Yuan, et al.
Published: (2021-01-01)

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
by: William P. McGuire, et al.
Published: (2018-12-01)

Effect of the Combination of Trabectedin and Pegylated Liposomal Doxorubicin in a BRCA2 Mutation Carrier with Recurrent Platinum-Sensitive Ovarian Cancer
by: María Jesús Rubio Pérez
Published: (2017-05-01)

The efficiency of trabectedin in the monotherapy and combinations in the treatment of advanced ovarian cancer
by: M V Cherkasova, et al.
Published: (2013-12-01)

Evaluation of Pegylated Liposomal Doxorubicin in the Treatment Of Both Platinum- and Paclitaxel-Refractory Epithelial Ovarian Cancer
by: Hao Lin, et al.
Published: (2004-09-01)

Exploring the Use of Pegylated Liposomal Doxorubicin (Caelyx®) as Pressurized Intraperitoneal Aerosol Chemotherapy
by: Manuela Robella, et al.
Published: (2019-06-01)

An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population
by: Yang SHEN, Zhixiang SHEN, Bin JIANG, et al.
Published: (2009-12-01)

Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer
by: Bradley J. Monk, et al.
Published: (2020-06-01)

EXTRAVASATION OF PEGYLATED-LIPOSOMAL DOXORUBICIN: FAVORABLE OUTCOME AFTER IMMEDIATE SUBCUTANEOUS ADMINISTRATION OF CORTICOSTEROIDS
by: ANDO, YUICHI, et al.
Published: (2012)

Comparable efficacy and less toxicity of pegylated liposomal doxorubicin versus epirubicin for neoadjuvant chemotherapy of breast cancer: a case-control study
by: Dong M, et al.
Published: (2018-07-01)

Maintenance with Trabectedin in the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer
by: Eva María Guerra Alía, et al.
Published: (2019-06-01)

Meta-Analysis of Trials Comparing Gemcitabine and Pegylated Liposomal Doxorubicin for Treatment in Women with Progressive or Recurrent Ovarian Cancer
by: Xia LIU, et al.
Published: (2009-12-01)

Pegylated Liposomal Doxorubicin as a Single Agent or as Combination Therapy with Carboplatin in Patients with Recurrent or Refractory Epithelial Ovarian Cancer
by: Keng SHEN, et al.
Published: (2009-12-01)

Place of pegylated liposomal doxorubicin in the therapy of metastatic breast cancer
by: E. V. Artamonova
Published: (2016-09-01)

Gemcitabine–oxaliplatin (GEMOX) for epithelial ovarian cancer patients resistant to platinum-based chemotherapy
by: Mohamed Elshebeiny, et al.
Published: (2016-09-01)

Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients
by: Ondřej Kubeček, et al.
Published: (2015-07-01)

Atypical case of hand foot syndrome due to pegylated liposomal doxorubicin presenting as hyperpigmentation
by: Manjeet Naresh Ramteke, et al.
Published: (2015-01-01)

IS HIPEC BENEFICIAL IN PLATINUM RESISTANT RELAPSED OVARIAN CANCER?
by: Nicolae Bacalbasa, et al.
Published: (2019-09-01)

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers
by: Eleonora Ghisoni, et al.
Published: (2019-02-01)

A Dose Escalation Study of Trientine Plus Carboplatin and Pegylated Liposomal Doxorubicin in Women With a First Relapse of Epithelial Ovarian, Tubal, and Peritoneal Cancer Within 12 Months After Platinum-Based Chemotherapy
by: Yu-Fang Huang, et al.
Published: (2019-05-01)

The quality of life of patients with ovarian cancer as an indicator of functional assessing the effectiveness of anticancer therapy
by: O. O. Kolesnik, et al.
Published: (2017-05-01)

The impact of Pegylated liposomal doxorubicin in recurrent ovarian cancer: an updated meta-analysis of randomized clinical trials
by: Xin-Ru Li, et al.
Published: (2021-03-01)

Salvage Chemotherapy in Recurrent Cervical Cancer With Biweekly Pegylated Liposomal Doxorubicin (Lipo-Dox)
by: Jen-Ruei Chen, et al.
Published: (2008-09-01)

Neoadjuvant Combination Chemotherapy with Pegylated Liposomal Doxorubicin and Vinorelbine for Locally Advanced Breast Cancer
by: Zhen-zhou SHEN, et al.
Published: (2010-02-01)

Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice
by: Christoffer Stark, et al.
Published: (2018-02-01)

Synthesis and characterisation of novel platinum (II) complexes potential chemotherapeutic drugs
by: Datt, Michael Steven
Published: (2001)

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study
by: Miguel J. Gil-Gil, et al.
Published: (2021-07-01)

Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data
by: Sibel Oyucu Orhan, et al.
Published: (2021-02-01)

Recurrent Meningioma of the Cervical Spine, Successfully Treated with Liposomal Doxorubicin
by: William L. Read, et al.
Published: (2017-07-01)

Real-life experience using trabectedin plus pegylated liposomal doxorubicin combination to treat patients with relapsed ovarian cancer
by: Saad Tahir
Published: (2014-12-01)

Practical aspects of treating relapsed BRCA-associated ovarian cancer
by: A. A. Rumyantse, et al.
Published: (2019-12-01)

Pegylated Liposomal Doxorubicin Versus Epirubicin as Adjuvant Therapy for Stage I–III Breast Cancer
by: Wenxian Hu, et al.
Published: (2021-09-01)

A Novel Approach on Drug Delivery: Investigation of A New Nano-Formulation of Liposomal Doxorubicin and Biological Evaluation of Entrapped Doxorubicin on Various Osteosarcoma Cell Lines
by: Fateme Haghiralsadat, et al.
Published: (2017-05-01)

Pegylated Liposomal Doxorubicin in Vindesine-Based and Bortezomib-Based Regimens for Patients With Newly Diagnosed Multiple Myeloma: A Retrospective Study of Efficacy and Safety
by: Yujia Zhai, et al.
Published: (2021-03-01)

Preparation and evaluation of cyclodextrin polypseudorotaxane with PEGylated liposome as a sustained release drug carrier
by: Kayoko Hayashida, et al.
Published: (2014-11-01)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
by: Weng CS, et al.
Published: (2019-11-01)

Serum lactate dehydrogenase is a possible predictor of platinum resistance in ovarian cancer
by: Asami Ikeda, et al.
Published: (2020-11-01)

Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin
by: Hu X, et al.
Published: (2021-01-01)

Pegylated Liposomal Doxorubicin-Induced Acute Transient Encephalopathy in a Patient with Breast Cancer: A Case Report
by: Michelle Baker, et al.
Published: (2014-03-01)

Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer
by: Francesco Schettini, et al.
Published: (2021-09-01)

Cannot write session to /tmp/vufind_sessions/sess_gn448qgqie07luck09gevm1fi4